The kidney damage from C3 glomerulopathy happens when your body’s complement system goes into overdrive. Here’s how it impacts your kidneys.

Current treatment methods for C3 glomerulopathy (C3G) help support kidney function and suppress immune system activity. Emerging therapies interrupt the proteins responsible for disease activity.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

How does C3 glomerulopathy affect the body, and why is this progressive kidney disease so rare? We don't know exactly why it is so rare because we frankly don't know why some people actually ...

Findings from the APPEAR-C3G trial showed a 35% reduction in 24-hour UPCR from baseline (primary endpoint) in the iptacopan group compared with the placebo group. The Food and Drug Administration ...

C3 Glomerulopathy: Diagnosing a Rare and Variable Disease Nonspecific signs on a medical exam may point to C3 glomerulopathy, a rare disease with a variable course ranging from quiescence to ...

(RTTNews) - Novartis AG (NVS) announced that the U.S. Food and Drug Administration has approved oral Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy to reduce ...

About C3 glomerulopathy (C3G) Each year, approximately 1-2 people per million worldwide are newly diagnosed with C3G, a form of membranoproliferative glomerulonephritis (MPGN)3. In C3G ...

Oral Fabhalta (iptacopan), developed by Novartis, has been approved by FDA for treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria in those patients, the first approved treatment ...

FABHALTA is a prescription medicine used to treat adults with a kidney disease called complement 3 glomerulopathy (C3G), to reduce protein in the urine (proteinuria). It is not known if FABHALTA ...

Novartis (NYSE:NVS) announced Friday that the European Medicines Agency (EMA), endorsed Fabhalta for the treatment of adults ...